Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

Investors clamouring for exposure to US technology firms drove structured products volumes to record heights in 2024, underlining how the tech and AI frenzy has permeated the complex ecosystem ...

Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...

IPO content provided by Renaissance Capital LLC, manager of the IPO-focused ETFs (tickers: IPO, IPOs).